A Randomized Phase II Trial of Adjuvant Nivolumab with or Without Cabozantinib in Patients with Resected Mucosal Melanoma
A091903 is closed to accrual to Step 0 (Registration), effective June 3, 2026, at 4:00 PM ET.
A091903 is closed to accrual to Arm 3, effective May 14, 2026
